SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotypeDario Bongiovanni, Isabell Bernlochner, Melissa Klug et al.|Cell Death and Disease|2021Cited by 98
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, Jeffrey J. Stoddard, An Vandebosch et al.|The Lancet Infectious Diseases|2022Cited by 88
National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline reviewCarlijn Jordans, Karen Champenois, Emmanuelle Papot et al.|Eurosurveillance|2022Cited by 32
Platelet Surface Protein Expression and Reactivity upon TRAP Stimulation after BNT162b2 VaccinationMelissa Klug, Dario Bongiovanni, Olga Lazareva et al.|Thrombosis and Haemostasis|2021Cited by 14
LB01 SIX WEEKS OF SOFOSBUVIR/LEDIPASVIR TREATMENT OF ACUTE HEPATITIS C VIRUS GENOTYPE 1 MONOINFECTION: FINAL RESULTS OF THE THE GERMAN HEPNET ACUTE HCV IV STUDYKatja Deterding, Maurizio Degiuli, Christoph D. Spinner et al.|United European Gastroenterology Journal|2016Cited by 5